Good morning, HealthTech insiders. A smartphone treatment for schizophrenia just cleared the FDA for a symptom group that medication often struggles to address: the loss of motivation, pleasure and social engagement. Click Therapeutics’ Motivista is designed to work alongside ongoing clinical care. In its pivotal trial, people using the app improved more than those using a digital control over 16 weeks. The next test is whether patients can access it and sustain the benefit beyond the trial.
Two other developments are pushing care into earlier decisions. Genmab and AbbVie reported that adding epcoritamab to frontline R-CHOP reduced the risk of lymphoma progression or death in a Phase 3 trial. HeartBeam received Breakthrough Device Designation for a proposed way to help physicians assess possible heart attacks while patients are still at home. Each has reached a different milestone: an authorized digital treatment, a positive trial result, and a device indication still in development.
In today's Signal:
Click Therapeutics’ Motivista: The FDA clears a prescription digital therapeutic for negative symptoms of schizophrenia as an addition to clinician-managed outpatient care.
Genmab and AbbVie’s epcoritamab: Adding the bispecific antibody to R-CHOP reduces the risk of progression or death by 51% versus R-CHOP alone in newly diagnosed patients studied in EPCORE DLBCL-2.
HeartBeam’s at-home ECG program: Breakthrough Device Designation advances development of a proposed heart-attack assessment use; that use has not been cleared.
Follow the Money: RougeTx, WhiteLab Genomics and Vocca announce financing totaling $104 million for vascular therapeutics, genomic medicine design and medical-practice voice AI.
In partnership with
The best marketing ideas come from marketers who live it.
That’s what this newsletter delivers.
The Marketing Millennials is a look inside what’s working right now for other marketers. No theory. No fluff. Just real insights and ideas you can actually use—from marketers who’ve been there, done that, and are sharing the playbook.
Every newsletter is written by Daniel Murray, a marketer obsessed with what goes into great marketing. Expect fresh takes, hot topics, and the kind of stuff you’ll want to steal for your next campaign.
Because marketing shouldn’t feel like guesswork. And you shouldn’t have to dig for the good stuff.
LATEST DEVELOPMENTS
DIGITAL THERAPEUTICS & NEUROPSYCHIATRY
1. FDA Clears Click Therapeutics’ Motivista for Negative Symptoms of Schizophrenia
A screen from Motivista, Click Therapeutics’ prescription digital therapeutic for negative symptoms of schizophrenia. Image: Click Therapeutics.
The FDA has granted 510(k) clearance to Motivista (CT-155), a prescription digital therapeutic for adults with schizophrenia whose positive symptoms are clinically stable. Its indicated use is as an adjunct to clinician-managed outpatient care, including antipsychotic treatment. Negative symptoms can include reduced motivation, diminished pleasure and social withdrawal.
The details:
In the 457-person CONVOKE trial, the average improvement on the CAINS-MAP negative-symptom measure was 6.8 points with Motivista versus 4.2 points with a digital control at 16 weeks. The between-group difference was 2.6 points; the reported effect size was small to moderate.
Click describes the difference between the groups’ improvements as a 62% relative improvement. That does not mean patients’ symptoms fell by 62%.
About 70% of Motivista users maintained the trial’s adherence threshold through week 15. The company reported no serious treatment-related adverse events, while its safety information also records possibly related events in one participant. Longer-term benefit and use outside the trial remain under study.
The Signal: Motivista gives clinicians an authorized option directed at symptoms that can persist despite treatment of hallucinations or delusions. Clearance establishes an additional treatment route; it does not yet settle how widely the app will be prescribed, reimbursed or used over time.
TARGETED ONCOLOGY & IMMUNOTHERAPY
2. Epcoritamab Plus R-CHOP Improves Progression-Free Survival in Frontline Lymphoma Trial
EPKINLY (epcoritamab) product packaging. AbbVie and Genmab have reported Phase 3 results for its use with R-CHOP in newly diagnosed DLBCL. Image: AbbVie Canada.
Genmab and AbbVie reported positive topline results from Phase 3 EPCORE DLBCL-2. The study compared fixed-duration, subcutaneous epcoritamab plus R-CHOP with R-CHOP alone in newly diagnosed large B-cell lymphoma patients with International Prognostic Index scores of 2–5. The combination remains investigational for this frontline use.
The details:
In the overall studied population, the companies reported a 51% relative reduction in the risk of progression or death: hazard ratio 0.49, 95% confidence interval 0.36–0.67, p<0.0001.
The trial also met its primary progression-free survival endpoint in the higher-risk IPI 3–5 population. These are topline results; fuller efficacy, safety and follow-up data are still needed to assess the regimen.
The companies plan to engage regulators. The result does not amount to a frontline approval or establish an overall-survival benefit.
The Signal: This is a meaningful test of whether T-cell redirection can improve initial treatment while retaining R-CHOP as the chemotherapy backbone. Its eventual place in care will depend on the complete data, regulatory decisions and comparisons with other frontline options, including pola-R-CHP.
CARDIOVASCULAR DIAGNOSTICS
3. HeartBeam Gains Breakthrough Designation for Proposed At-Home Heart-Attack Assessment
A patient demonstrates HeartBeam’s portable ECG device. Its proposed heart attack assessment use has FDA Breakthrough Device Designation; it has not received clearance for that use. Image: HeartBeam.
The FDA has granted Breakthrough Device Designation to HeartBeam’s program for helping physicians assess a possible myocardial infarction outside the hospital. The designation gives the company more structured interaction with the FDA as it develops evidence and a pivotal study. It is not authorization to market the system for heart-attack detection.
The details:
HeartBeam’s portable system records cardiac electrical signals in three dimensions and uses software to produce a synthesized 12-lead ECG representation.
The designation was supported by proof-of-concept work and findings from the 134-patient ALIGN-ACS pilot study. HeartBeam says it will seek FDA agreement on a multicenter pivotal study.
The system and synthesis software have existing FDA clearance for specified non-life-threatening arrhythmia assessment. Their cleared labeling explicitly excludes myocardial infarction and ischemia assessment.
The Signal: The clinical problem is real: people with possible heart-attack symptoms may delay seeking help. HeartBeam is testing whether its portable ECG approach can give physicians useful information sooner. The pivotal question is diagnostic performance in the intended setting, followed by a separate FDA decision on the proposed use.
QUICK HITS
👀 WHAT WE'RE WATCHING NEXT
Motivista access and durability: Whether Click secures payer coverage and reports sustained benefit from longer-term follow-up after the 16-week controlled trial.
Epcoritamab’s full dataset: Safety, progression-free survival follow-up and subsequent regulatory submissions will show how far the topline result can move frontline practice.
HeartBeam’s pivotal plan: FDA alignment on study design, enrollment and performance thresholds for assessing possible myocardial infarction outside hospital care.
💰 FOLLOW THE MONEY
The deals:
RougeTx: $58 million Series A: The preclinical company is advancing RTX-001, designed to address pericyte dysfunction and stabilize fragile blood vessels in hereditary hemorrhagic telangiectasia. The financing was co-led by BioGeneration Ventures, Angelini Ventures, EIB’s Aurea co-investment facility and Kurma Partners.
WhiteLab Genomics: $26 million Series B: Led by AVP, the round will support experimental validation of AI-designed viral and non-viral delivery technologies and programmable genetic payloads.
Vocca: $20 million Series A: Led by Norrsken VC, the financing supports voice AI for patient communications and medical-practice operations.
The pattern: These investments target specific delivery, biology and practice-workflow problems. The financing is evidence of investor interest; each company still has to demonstrate that its approach works at the scale and cost its customers need.
📆 UPCOMING HEALTHTECH EVENTS
World Health Summit 2026: October 11–13 | Berlin and online. Global health leaders will discuss resilience, innovation and more equitable health systems.
Frontiers Health 2026: October 20–21 | bcc Berlin Congress Center, Berlin. A European forum for digital health, therapeutics and industry partnerships.
HLTH USA 2026: November 15–18 | The Venetian Expo, Las Vegas. A gathering of health systems, payers, founders and investors focused on healthcare innovation.
🛠️ Trending HealthTech AI Tools
AIRS Medical SwiftSight Body Composition: FDA-cleared MRI analysis software measuring muscle and fat compartments, including visceral and subcutaneous fat. AIRS says SimonMed Imaging will be its first deployment customer.
WhiteLab Genomics ALFRED: An AI platform for designing delivery vehicles and genetic payloads, with candidates subsequently tested experimentally. Its current work includes viral and non-viral approaches.
calliora Pre-Bill Audit Engine: Software aimed at finding coding and documentation issues before hospital claims are sent to payers. Its performance and deployment scale still need independent validation.
🛠️ Trending HealthTech AI Startups
RougeTx: Developing RTX-001 for hereditary hemorrhagic telangiectasia; the lead program is advancing toward first-in-human testing, rather than being an established treatment.
Vocca: Building voice agents for medical-practice calls, scheduling and patient communication following its $20 million Series A.
HeartBeam: Developing a portable ECG platform. Its proposed heart-attack assessment indication has Breakthrough Device Designation and still requires clinical validation and authorization.
DECISION INTELLIGENCE
Highlights: Deep Dives & Industry Reports
Neuroplasticity by Prescription: How Motivista Unlocks Negative Symptoms in Schizophrenia
What the controlled trial measured, how the prescription app fits alongside medication, and which access and durability questions remain.Dismantling the 25-Year R-CHOP Monopoly: Frontline Bispecifics and the Future of Lymphoma
What EPCORE DLBCL-2 establishes about progression-free survival, and what fuller data and regulatory review must establish next.Bridging the Last Mile of Acute Cardiology: Synthesized 3D Vectorcardiography at Home
The potential of earlier ECG assessment, the limits of HeartBeam’s current clearance, and the evidence needed for a heart-attack indication.
Which of today’s innovations faces the toughest path into routine care?
That's it for today!
A patient with schizophrenia may soon have a prescribed tool aimed specifically at motivation and social engagement. A lymphoma trial has shown a substantial improvement in progression-free survival when epcoritamab is added to frontline treatment. And a portable ECG company has been given a faster channel to work with the FDA on a possible at-home heart-attack assessment.
The distance from milestone to routine care differs in each case. Motivista needs access and lasting use; epcoritamab needs full data and a regulatory decision; HeartBeam needs a pivotal study and authorization for its proposed use. Those next steps will tell us which of today’s promising developments changes what patients can actually receive.
How did we do today?
See you tomorrow,
Dr. Dereck Mush, MD, MBA
The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.
Was this email forwarded to you? Sign up here.
Until tomorrow,
The HealthTech Signal